PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: CP-690-550
Drug: CP-690,550
Drug: Placebo
Drug: Adalimumab

First Posted Date: 2007-10-29

Last Posted Date: 2013-01-03

Lead Sponsor: Pfizer

Target Recruit Count: 386

Registration Number: NCT00550446

Locations: 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine

Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets

Completed

Conditions: Diabetes Mellitus, Non-Insulin-Dependent
Hyperglycemia

First Posted Date: 2007-10-29

Last Posted Date: 2008-10-21

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT00550329

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: Macugen

First Posted Date: 2007-10-25

Last Posted Date: 2018-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 38

Registration Number: NCT00549055

Locations: 🇧🇪
Pfizer Investigational Site, Liege, Belgium

PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib

Phase 2

Completed

Conditions: Carcinoma, Non Small Cell Lung

Interventions: Drug: PF-00299804

First Posted Date: 2007-10-23

Last Posted Date: 2019-05-21

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00548093

Locations: 🇺🇸
Grady Health Systems, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 16 locations

This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis

Phase 4

Completed

Conditions: Candidemia
Invasive Candidiasis

Interventions: Drug: Anidulafungin
Drug: Voriconazole

First Posted Date: 2007-10-23

Last Posted Date: 2011-01-17

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT00548262

Locations: 🇵🇦
Pfizer Investigational Site, Panama, Panama

Fesoterodine "add-on" Male Overactive Bladder Study

Phase 3

Completed

Conditions: Overactive Bladder Syndrome

Interventions: Drug: Placebo
Drug: Fesoterodine

First Posted Date: 2007-10-19

Last Posted Date: 2011-02-18

Lead Sponsor: Pfizer

Target Recruit Count: 947

Registration Number: NCT00546637

Locations: 🇹🇭
Pfizer Investigational Site, Amphoe Mueang, Chiang Mai, Thailand

First Safety Study in Humans of a Single Dose of CPG 52364

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 52364 3 mg
Drug: 52364 30 mg
Drug: 52364 1 mg
Drug: 52364 100 mg
Drug: 52364 10 mg

First Posted Date: 2007-10-19

Last Posted Date: 2009-03-19

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT00547014

Locations: 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States

A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone

Phase 2

Completed

Conditions: Palliative Care
Neoplasm Metastasis

Interventions: Drug: Tanezumab 10 mg IV
Drug: IV Placebo for tanezumab

First Posted Date: 2007-10-17

Last Posted Date: 2021-06-18

Lead Sponsor: Pfizer

Target Recruit Count: 59

Registration Number: NCT00545129

Locations: 🇱🇻
10th Department, Latvian Oncological Centre / Riga Eastern Clinical University Hospital, Riga, Latvia
🇮🇳
Shatabdi Superspeciality Hospital, Nashik, Maharashtra, India
🇸🇰
Narodny onkologicky ustav, Bratislava, Slovakia

and more 36 locations

Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Etanercept

First Posted Date: 2007-10-16

Last Posted Date: 2015-05-12

Lead Sponsor: Pfizer

Target Recruit Count: 1715

Registration Number: NCT00544557

Locations: 🇩🇪
Klinikum Benjamin Franklin, Berlin, Germany

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Biological: Moroctocog alfa (AF-CC)

First Posted Date: 2007-10-15

Last Posted Date: 2019-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT00543439

Locations: 🇹🇷
Istanbul Universtesi Istanbul Tip Fakultesi, Capa, Istanbul, Turkey
🇷🇴
Sanador, Bucuresti, Romania
🇹🇷
Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey

and more 25 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy